Literature DB >> 23078655

Permanent pacing in patients with Chagas' disease.

Mauricio Arce1, Jorge VAN Grieken, Francisco Femenía, Martín Arrieta, William F McIntyre, Adrian Baranchuk.   

Abstract

BACKGROUND: Chagas' disease is an endemic disease in most Latin American countries. The cardiomyopathy associated with this condition often requires permanent pacing due to bradycardia. The aim of this study was to compare the indications for pacemaker implantation, intraoperative measurements, and long-term follow-up of patients with Chagas' cardiomyopathy (ChCM) and ischemic cardiomyopathy (ICM) referred for pacemaker implantation.
METHODS: Retrospective study including consecutive patients with ChCM (Group 1) and ICM (Group 2), who underwent pacemaker implantation in a single center.
RESULTS: We analyzed 360 patients. Patients in Group 1 were younger (66.29 ± 7.01 vs 75.3 ± 7.11 years; P = 0.0001) and more often male (72% vs 60%; P = 0.05). Sinus node dysfunction (SND) was more prevalent in Group 1 (70% vs 52%; P = 0.03). Atrioventricular block was less prevalent in Group 1 (30% vs 48%; P = 0.04). No significant differences were found with respect to left ventricular ejection fraction (54.2 ± 9.1 vs 53.4 ± 8.2%; P = NS) and baseline QRS duration (119 ± 34 vs 108 ± 29 ms; P = NS). Right bundle branch block was more frequent in Group 1 (44% vs 12%; P = 0.0001), and left bundle branch block in Group 2 (6% vs 22%; P = 0.0001). Implantation time was longer in Group 1 (39 ± 19 vs 29 ± 13 minutes; P = 0.001) and was with higher atrial and ventricular pacing thresholds (1.4 ± 0.8 vs 1.0 ± 0.5 V; P = 0.001 and 1.2 ± 0.8 vs 0.6 ± 0.8 V; P = 0.001, respectively). During a follow-up of 42.8 ± 13.6 months, Group 1 had a higher incidence of new atrial fibrillation (34% vs 25.5%; P = 0.001), and there was a nonsignificant trend toward more displacements of the ventricular lead (6% vs 3.5%; P = 0.3). There were no deaths during the follow-up.
CONCLUSIONS: ChCM patients receiving pacemakers are younger and more frequently have SND compared to those with ICM. Pacemaker implant is longer in patients with ChCM disease and is with higher pacing thresholds. The incidence of new atrial fibrillation during the follow-up is significantly higher in patients with ChCM. ©2012, The Authors. Journal compilation ©2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23078655     DOI: 10.1111/pace.12013

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  5 in total

1.  The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California.

Authors:  Sandy Park; Daniel R Sanchez; Mahmoud I Traina; Jason S Bradfield; Salvador Hernandez; Alvaro Joaquin Altamirano Ufion; Jalal Dufani; Patrick Bergin; Robin Y Wachsner; Sheba K Meymandi
Journal:  Am J Trop Med Hyg       Date:  2017-05       Impact factor: 2.345

2.  Chronotropic incompetence in Chagas disease: effectiveness of blended sensor (volume/minute and accelerometer).

Authors:  Antonio da Silva Menezes Junior; Aline Pereira da Silva; Giovana Gurian Batista Profahl; Catarine Ottobeli; Jutay Fernando Silva Louzeiro
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jul-Sep

Review 3.  Congenital and childhood atrioventricular blocks: pathophysiology and contemporary management.

Authors:  Alban-Elouen Baruteau; Robert H Pass; Jean-Benoit Thambo; Albin Behaghel; Solène Le Pennec; Elodie Perdreau; Nicolas Combes; Leonardo Liberman; Christopher J McLeod
Journal:  Eur J Pediatr       Date:  2016-06-28       Impact factor: 3.183

4.  Age-related anomalies of electrocardiograms in patients from areas with differential Seroprevalence of Chagas disease in Southern Bolivia.

Authors:  Jhean-Carla Echalar; David Veliz; Omar N Urquizo; Hermann M Niemeyer; Carlos F Pinto
Journal:  Parasite Epidemiol Control       Date:  2021-02-03

5.  [Repetition presyncopes in Bolivian woman].

Authors:  Raquel Basquero-Álvarez; Juan González-Moreno; Carmen Cifuentes-Luna; Javier Fosch-Mur
Journal:  Aten Primaria       Date:  2015-10-29       Impact factor: 1.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.